What is enVVeno Medical Corporation's earnings per share (EPS)?

enVVeno Medical Corporation (NVNO) reported diluted earnings per share of -$33.06 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

enVVeno Medical Corporation (NVNO) Financials

NVNO

FY2025 annual

Net Income -$19.5M +10.8% YoY

EPS (Diluted) -$33.06 YoY not available

Free Cash Flow -$15.6M +7.7% YoY

Operating Cash Flow -$15.6M +7.5% YoY

Market Cap $6.1M as of Oct 10, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.3x on $20.7M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 30, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NVNO SEC filings page.

This page shows enVVeno Medical Corporation (NVNO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NVNO FY2025 2026-10-04

The company is posting narrowing losses with minimal capital spending, but still uses cash to fund its recurring cost base.

Net loss narrowed from $21.8M in FY2024 to $19.5M in FY2025, but operating cash flow remained negative. The FY2025 operating cash flow of -$15.6M was almost entirely free cash flow because capital expenditures were only $5K, showing that cash use reflects ongoing operations rather than a heavy investment build-out.

R&D and SG&A totaled $20.9M in FY2025, nearly matching the $20.9M operating loss; this indicates the business is still funding a substantial operating program before revenue generation is visible in the reported data.

FY2025 liabilities were $2.4M against $29.6M of assets, indicating a lightly debt-funded balance sheet. Assets fell from $45.0M in FY2024 to $29.6M in FY2025, pointing to resource consumption rather than balance-sheet expansion.

Financial Health Signals

Financial health score not available

enVVeno Medical Corporation does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

enVVeno Medical Corporation passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

enVVeno Medical Corporation reported a net loss of $19.5M while operations used $15.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$3.6M

YoY+46.2%

QoQ+6.5%

enVVeno Medical Corporation reported -$3.6M in net income in Q2 2026. This represents an increase of 46.2% from the same quarter a year earlier. Against the prior quarter it is up 6.5%.

EPS (Diluted)

-$5.37

QoQ+8.8%

enVVeno Medical Corporation earned -$5.37 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 8.8%.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$2.8M

YoY+39.0%

QoQ+9.4%

5Y CAGR-41.4%

enVVeno Medical Corporation held $2.8M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

682,722

QoQ+2.3%

5Y CAGR-39.6%

enVVeno Medical Corporation had 682,722 shares outstanding in Q2 2026. Against the prior quarter it is up 2.3%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-17.4%

YoY+2.8pp

QoQ-1.2pp

enVVeno Medical Corporation's ROE was -17.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 2.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.2 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$2.1M

YoY-28.2%

QoQ-1.7%

enVVeno Medical Corporation invested $2.1M in research and development in Q2 2026. This represents a decrease of 28.2% from the same quarter a year earlier. Against the prior quarter it is down 1.7%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

NVNO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NVNO quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$31K-83.3%	$187K-55.8%	$422K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$420K
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$187K+7508.2%	$2K
R&D Expenses	N/A	$10.0M-18.5%	$12.2M-9.8%	$13.6M+37.0%	$9.9M+73.1%	$5.7M+34.7%	$4.3M+92.7%	$2.2M+78.1%	$1.2M+90.7%	$650K
SG&A Expenses	N/A	$10.9M-5.7%	$11.6M-0.7%	$11.7M-22.4%	$15.0M+34.5%	$11.2M+128.7%	$4.9M-0.6%	$4.9M-24.2%	$6.5M+18.8%	$5.5M
Operating Income	N/A	-$20.9M+12.3%	-$23.8M+5.6%	-$25.2M-1.2%	-$24.9M-47.6%	-$16.9M-84.9%	-$9.1M-19.0%	-$7.7M+2.3%	-$7.9M-28.7%	-$6.1M
EBITDA	N/A	-$20.8M+12.2%	-$23.6M+5.5%	-$25.0M-1.2%	-$24.7M-47.6%	-$16.7M-85.3%	-$9.0M-19.7%	-$7.6M+2.2%	-$7.7M-29.5%	-$6.0M
Interest Expense	N/A	N/A	N/A	N/A	$161K+747.4%	$19K+408.2%	$4K+107.5%	-$50K-116.3%	$305K+76.8%	$173K
Net Income	N/A	-$19.5M+10.8%	-$21.8M+7.2%	-$23.5M+4.7%	-$24.7M-49.3%	-$16.5M-80.9%	-$9.1M-19.8%	-$7.6M+41.5%	-$13.0M-67.4%	-$7.8M
EPS (Basic)	N/A	-$33.06+25.8%	-$44.53-2231.4%	-$1.91+13.2%	-$2.20-15.8%	-$1.90	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$33.06	-$44.53	-$1.91+13.2%	-$2.20	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	589,000	490,000	12M+9.5%	11M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$2.1M-28.2%	$2.1M-17.4%	N/A	$2.6M-9.6%	$2.9M+2.3%	$2.6M-16.2%	N/A	$2.9M+2.2%
SG&A Expenses	$1.7M-58.6%	$2.0M-18.6%	N/A	$2.3M-30.6%	$4.2M+58.2%	$2.4M-2.2%	N/A	$3.3M+29.8%
Operating Income	-$3.8M+46.1%	-$4.1M+18.0%	N/A	-$4.9M+20.9%	-$7.0M-29.2%	-$5.0M+10.0%	N/A	-$6.2M-15.3%
EBITDA	N/A	-$4.0M+18.0%	N/A	-$4.9M+20.8%	-$7.0M-29.8%	-$4.9M+9.8%	N/A	-$6.1M-15.8%
Net Income	-$3.6M+46.2%	-$3.8M+14.5%	N/A	-$4.5M+19.5%	-$6.7M-35.1%	-$4.5M+9.8%	N/A	-$5.6M-12.8%
EPS (Basic)	-$5.37+53.4%	-$5.89+24.0%	-$32.28-10660.0%	-$0.23+34.3%	-$11.52-3616.1%	-$7.75-2400.0%	-$0.30+6.3%	-$0.35+22.2%
EPS (Diluted)	-$5.37	-$5.89	-$32.28	-$0.23+34.3%	-$11.52	-$7.75	-$0.30+6.3%	-$0.35+22.2%
Diluted Shares (Avg)	671,000	654,000	N/A	20M+25.4%	581,000	581,000	N/A	16M+43.1%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

NVNO Balance Sheet

NVNO quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Total Assets	$29.6M-34.2%	$45.0M-7.6%	$48.6M+16.7%	$41.7M-27.8%	$57.7M+447.5%	$10.5M+206.8%	$3.4M-3.5%	$3.6M+60.7%	$2.2M
Current Assets	$28.8M-34.1%	$43.7M-6.8%	$46.9M+19.0%	$39.4M-28.4%	$55.0M+475.2%	$9.6M+572.0%	$1.4M-49.8%	$2.8M+1564.8%	$170K
Cash & Equivalents	$3.1M+74.7%	$1.8M-51.5%	$3.6M-20.5%	$4.6M-91.7%	$54.7M+486.3%	$9.3M+614.1%	$1.3M-52.3%	$2.7M+3427.8%	$78K
Short-Term Investments	$25.1M-39.3%	$41.4M-3.3%	$42.8M+24.1%	$34.5M	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$32K-9.0%	$35K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.4M-13.0%	$2.8M+14.8%	$2.4M-17.0%	$2.9M-11.0%	$3.3M-4.2%	$3.4M+40.7%	$2.4M+60.5%	$1.5M-88.6%	$13.3M
Current Liabilities	$2.1M+1.3%	$2.1M+52.8%	$1.4M-10.4%	$1.5M-3.2%	$1.6M-50.4%	$3.2M+69.8%	$1.9M+23.2%	$1.5M	N/A
Non-Current Liabilities	$310K-55.7%	$700K-34.2%	$1.1M-24.1%	$1.4M-18.3%	$1.7M+575.9%	$254K-55.3%	$568K	$0	N/A
Total Equity	$27.1M-35.6%	$42.2M-8.7%	$46.2M+19.3%	$38.7M-28.8%	$54.4M+666.5%	$7.1M+617.0%	$990K-51.4%	$2.0M+118.3%	-$11.1M
Retained Earnings	-$171.3M-12.8%	-$151.9M-16.8%	-$130.0M-22.1%	-$106.5M-30.1%	-$81.9M-25.3%	-$65.3M-16.3%	-$56.2M-15.7%	-$48.6M-36.7%	-$35.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$22.7M-38.0%	$26.1M-35.7%	$29.6M-34.2%	$32.4M-35.8%	$36.6M-10.8%	$40.6M-9.5%	$45.0M-7.6%	$50.4M+79.4%
Current Assets	$22.1M-38.0%	$25.5M-35.4%	$28.8M-34.1%	$31.5M-35.8%	$35.6M-9.9%	$39.5M-8.7%	$43.7M-6.8%	$49.1M+87.1%
Cash & Equivalents	$2.8M+39.0%	$2.6M-11.6%	$3.1M+74.7%	$1.5M-91.4%	$2.0M-14.1%	$2.9M+26.9%	$1.8M-51.5%	$17.9M+262.2%
Short-Term Investments	$18.6M-43.7%	$22.3M-38.0%	$25.1M-39.3%	$29.4M-3.5%	$33.1M-9.8%	$36.0M-11.4%	$41.4M-3.3%	$30.5M+46.8%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.0M-43.5%	$2.4M+3.5%	$2.4M-13.0%	$2.9M-3.8%	$3.5M+36.6%	$2.3M-7.7%	$2.8M+14.8%	$3.0M-5.0%
Current Liabilities	$1.9M-37.4%	$2.1M+29.0%	$2.1M+1.3%	$2.4M+7.7%	$3.0M+77.9%	$1.7M+11.7%	$2.1M+52.8%	$2.2M+9.7%
Non-Current Liabilities	$103K-79.6%	$207K-66.0%	$310K-55.7%	$505K-36.2%	$505K-42.7%	$609K-37.4%	$700K-34.2%	$791K-31.1%
Total Equity	$20.7M-37.5%	$23.7M-38.0%	$27.1M-35.6%	$29.4M-37.8%	$33.1M-14.0%	$38.3M-9.6%	$42.2M-8.7%	$47.4M+90.1%
Retained Earnings	-$178.8M-9.6%	-$175.2M-12.0%	-$171.3M-12.8%	-$167.6M-15.1%	-$163.1M-16.5%	-$156.4M-15.8%	-$151.9M-16.8%	-$145.6M-17.1%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

NVNO Cash Flow Statement

NVNO quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Operating Cash Flow	-$14.6M	-$15.6M+7.5%	-$16.8M+10.7%	-$18.9M-20.7%	-$15.6M-31.8%	-$11.8M-54.3%	-$7.7M-30.2%	-$5.9M+7.2%	-$6.4M-51.2%	-$4.2M
Depreciation & Amortization	N/A	$136K-28.0%	$189K-14.1%	$220K+3.8%	$212K+42.3%	$149K+52.7%	$98K-21.1%	$124K-7.3%	$133K-4.2%	$139K
Stock-Based Compensation	N/A	$3.4M-17.4%	$4.1M-20.3%	$5.2M-42.2%	$9.0M+49.9%	$6.0M+580.8%	$881K-6.4%	$942K-51.0%	$1.9M+118.9%	$878K
Capital Expenditures	N/A	$5K-86.5%	$37K+12.1%	$33K-71.3%	$115K-68.8%	$368K+104.1%	$180K-50.5%	$364K+2829.4%	$12K+13.6%	$11K
Free Cash Flow	N/A	-$15.6M+7.7%	-$16.9M+10.7%	-$18.9M-20.1%	-$15.7M-28.8%	-$12.2M-55.5%	-$7.9M-25.5%	-$6.3M+1.7%	-$6.4M-51.2%	-$4.2M
Investing Cash Flow	$14.3M	$15.9M+1087.7%	$1.3M+117.0%	-$7.9M+77.2%	-$34.6M-9289.7%	-$368K-104.1%	-$180K+50.5%	-$364K-2829.4%	-$12K-107.5%	$165K
Financing Cash Flow	N/A	$1.0M-92.5%	$13.6M-47.1%	$25.8M	N/A	$57.6M+282.1%	$15.1M+167.4%	$5.6M-37.6%	$9.0M+122.5%	$4.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$3.5M+4.5%	-$3.2M+19.4%	-$3.4M+32.6%	-$4.4M-2.7%	-$3.7M+4.9%	-$4.0M-13.2%	-$5.1M-2.7%	-$4.3M-1.5%
Depreciation & Amortization	N/A	$31K-22.5%	$31K-22.5%	$31K-27.9%	$34K-33.3%	$40K-27.3%	$40K-27.3%	$43K-23.2%
Stock-Based Compensation	N/A	$467K-28.3%	N/A	N/A	N/A	$651K-41.6%	N/A	N/A
Capital Expenditures	N/A	N/A	$0-100.0%	$0-100.0%	N/A	N/A	$4K0.0%	$9K+200.0%
Free Cash Flow	N/A	N/A	-$3.4M+32.6%	-$4.4M-2.5%	N/A	N/A	-$5.1M-2.7%	-$4.3M-1.6%
Investing Cash Flow	$3.7M+29.9%	$2.8M-46.7%	$4.2M+137.8%	$3.7M-41.3%	$2.8M-29.0%	$5.2M+136.6%	-$11.1M+50.1%	$6.2M+39.9%
Financing Cash Flow	N/A	N/A	$782K	N/A	N/A	N/A	$0	$13.6M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

NVNO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NVNO quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	100.0%+99.4pp	0.6%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	-24566.5%	-4210.5%	-1445.9%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	-24406.7%	-6991.5%	-1845.8%
Return on Equity	-71.8%-20.0pp	-51.7%-0.8pp	-50.9%+12.8pp	-63.7%-33.3pp	-30.4%+98.3pp	-128.7%+641.6pp	-770.3%-129.8pp	-640.5%	N/A
Return on Assets	-65.9%-17.3pp	-48.5%-0.2pp	-48.4%+10.9pp	-59.2%-30.6pp	-28.6%+58.0pp	-86.7%+135.4pp	-222.0%+144.4pp	-366.4%-14.7pp	-351.8%
Current Ratio	13.58-7.3x	20.88-13.4x	34.23+8.5x	25.78-9.1x	34.84+31.8x	3.00+2.2x	0.76-1.1x	1.86	N/A
Debt-to-Equity	0.090.0x	0.070.0x	0.050.0x	0.080.0x	0.06-0.4x	0.48-2.0x	2.47+1.7x	0.75	N/A
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	0.010.0x	0.05-0.1x	0.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-20037.4%	-3413.7%	-998.1%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-17.4%+2.8pp	-16.2%-4.5pp	N/A	-15.4%-3.5pp	-20.3%-7.4pp	-11.8%0.0pp	N/A	-11.9%+8.2pp
Return on Assets	-15.9%+2.4pp	-14.8%-3.6pp	N/A	-14.0%-2.8pp	-18.3%-6.2pp	-11.1%0.0pp	N/A	-11.2%+6.6pp
Current Ratio	11.70-0.1x	11.89-11.9x	13.58-7.3x	13.12-8.9x	11.81-11.5x	23.77-5.3x	20.88-13.4x	22.01+9.1x
Debt-to-Equity	0.100.0x	0.100.0x	0.090.0x	0.100.0x	0.110.0x	0.060.0x	0.070.0x	0.06-0.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
enVVeno Medical Corporation NVNO	FY2025	N/A	-$19.5M	N/A	$6.1M	—
Intelligent Bio Solutions Inc. INBS	FY2026	$4.2M	-$12.4M	N/A	$5.1M	40/100
Nexalin Technology, Inc. NXL	FY2025	$302K	-$8.2M	N/A	$3.8M	—
Ainos, Inc. AIMD	FY2025	$124K	-$14.8M	N/A	$8.9M	—
ALLURION TECHNOLOGIES ALUR	FY2025	$15.2M	-$28.8M	N/A	$10.0M	—
Beyond Air, Inc. XAIR	FY2026	$7.7M	-$33.2M	N/A	$2.2M	63/100

Where enVVeno Medical Corporation Ranks

Frequently Asked Questions

Is enVVeno Medical Corporation profitable?

No, enVVeno Medical Corporation (NVNO) reported a net income of -$19.5M in fiscal year 2025.

What is enVVeno Medical Corporation's EBITDA?

enVVeno Medical Corporation (NVNO) had EBITDA of -$20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is enVVeno Medical Corporation's return on equity (ROE)?

enVVeno Medical Corporation (NVNO) has a return on equity of -71.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is enVVeno Medical Corporation's free cash flow?

enVVeno Medical Corporation (NVNO) recorded an outflow of $15.6M in free cash flow during fiscal year 2025. This represents a 7.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is enVVeno Medical Corporation's operating cash flow?

enVVeno Medical Corporation (NVNO) recorded an outflow of $15.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are enVVeno Medical Corporation's total assets?

enVVeno Medical Corporation (NVNO) had $29.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are enVVeno Medical Corporation's capital expenditures?

enVVeno Medical Corporation (NVNO) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does enVVeno Medical Corporation spend on research and development?

enVVeno Medical Corporation (NVNO) invested $10.0M in research and development during fiscal year 2025.

How many shares does enVVeno Medical Corporation have outstanding?

enVVeno Medical Corporation (NVNO) had 655,521 shares outstanding as of fiscal year 2025.

What is enVVeno Medical Corporation's current ratio?

enVVeno Medical Corporation (NVNO) had a current ratio of 13.58 as of fiscal year 2025, which is generally considered healthy.

What is enVVeno Medical Corporation's debt-to-equity ratio?

enVVeno Medical Corporation (NVNO) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is enVVeno Medical Corporation's return on assets (ROA)?

enVVeno Medical Corporation (NVNO) had a return on assets of -65.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is enVVeno Medical Corporation's P/E ratio?

enVVeno Medical Corporation (NVNO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $6.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is enVVeno Medical Corporation's price-to-sales ratio?

enVVeno Medical Corporation (NVNO) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $6.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does enVVeno Medical Corporation's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, enVVeno Medical Corporation (NVNO) held $28.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $15.6M over that year. Dividing the one by the other, the reported balance equals about 22 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is enVVeno Medical Corporation's Piotroski F-Score?

enVVeno Medical Corporation (NVNO) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are enVVeno Medical Corporation's earnings high quality?

enVVeno Medical Corporation (NVNO) reported a net loss of $19.5M while operations used $15.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.